GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity
Sabine Heitzeneder, Kristopher R. Bosse, Zhongyu Zhu, Doncho V. Zhelev, Robbie G. Majzner, Molly Radosevich, Shaurya Dhingra, Elena Sotillo, Samantha N. Buongervino, Guillem Pascual‐Pasto, Emily Garrigan, Peng Xu, Jing Huang, Benjamin Salzer, Alberto Delaidelli, Swetha Raman, Hong Cui, Benjamin Martinez, Scott J. Bornheimer, Bita Sahaf, Anya S. Alag, Irfete S. Fetahu, Martin Hasselblatt, Kevin R. Parker, Hima Anbunathan, Jennifer Hwang, Min Huang, Kathleen M. Sakamoto, Norman J. Lacayo, Dorota D. Klysz, Johanna Theruvath, José G. Vilches-Moure, Ansuman T. Satpathy, Howard Y. Chang, Manfred Lehner, Sabine Taschner‐Mandl, Jean-Phillipe Julien, Poul H. Sorensen, Dimiter S. Dimitrov, John M. Maris, Crystal L. Mackall
Topics & Concepts
Chimeric antigen receptorNeuroblastomaAntigenCancer researchBiologyImmune systemCell cultureCell biologyImmunologyT cellGeneticsCAR-T cell therapy researchNeuroblastoma Research and TreatmentsVirus-based gene therapy research